In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
In the latest session, Legend Biotech Corp ADR (NASDAQ: LEGN) closed at $31.44 down -1.93% from its previous closing price of $32.06. In other words, the price has decreased by -$1.93 from its previous closing price. On the day, 1.09 million shares were traded. LEGN stock price reached its highest trading level at $32.615 during the session, while it also had its lowest trading level at $31.21.
Ratios:
For a deeper understanding of Legend Biotech Corp ADR’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.57 and its Current Ratio is at 4.71. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.37.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Redburn Atlantic on October 08, 2024, initiated with a Buy rating and assigned the stock a target price of $86.
On June 17, 2024, Truist started tracking the stock assigning a Buy rating and target price of $88.
H.C. Wainwright reiterated its Buy rating for the stock on May 24, 2024, while the target price for the stock was revised from $86 to $73.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 26 ’25 when Casey Patrick John bought 1,000 shares for $33.28 per share.
Huang Ying bought 1,370 shares of LEGN for $45,210 on Sep 24 ’25. On Sep 23 ’25, another insider, Huang Ying, who serves as the Officer of the company, bought 1,357 shares for $33.98 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 5802903040 and an Enterprise Value of 11026162688. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.27 while its Price-to-Book (P/B) ratio in mrq is 5.60. Its current Enterprise Value per Revenue stands at 13.837 whereas that against EBITDA is -52.753.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.18, which has changed by -0.34581774 over the last 52 weeks, in comparison to a change of 0.1719923 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $51.77, while it has fallen to a 52-week low of $27.34. The 50-Day Moving Average of the stock is -11.26%, while the 200-Day Moving Average is calculated to be -10.00%.
Shares Statistics:
For the past three months, LEGN has traded an average of 1.22M shares per day and 1213360 over the past ten days. A total of 184.57M shares are outstanding, with a floating share count of 180.77M. Insiders hold about 2.06% of the company’s shares, while institutions hold 44.87% stake in the company. Shares short for LEGN as of 1757894400 were 9686681 with a Short Ratio of 7.97, compared to 1755216000 on 7586207. Therefore, it implies a Short% of Shares Outstanding of 9686681 and a Short% of Float of 10.03.
Earnings Estimates
. The current rating of Legend Biotech Corp ADR (LEGN) is the result of assessments by 5.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.06, with high estimates of -$0.0 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.08 and -$1.46 for the fiscal current year, implying an average EPS of -$0.68. EPS for the following year is $0.48, with 7.0 analysts recommending between $0.89 and $0.29.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $278.68M this quarter.It ranges from a high estimate of $314.19M to a low estimate of $231.4M. As of. The current estimate, Legend Biotech Corp ADR’s year-ago sales were $160.21MFor the next quarter, 11 analysts are estimating revenue of $331.11M. There is a high estimate of $399.06M for the next quarter, whereas the lowest estimate is $280M.
A total of 16 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $1.14B, while the lowest revenue estimate was $945.6M, resulting in an average revenue estimate of $1.05B. In the same quarter a year ago, actual revenue was $627.24MBased on 16 analysts’ estimates, the company’s revenue will be $1.58B in the next fiscal year. The high estimate is $1.95B and the low estimate is $1.45B.
